Introduction {#Sec1}
============

If surgery is the "neglected stepchild of global health" \[[@CR1]\], pediatric surgery is the child not yet born. Despite powerful strides forward in the treatment of congenital anomalies, or birth defects, the benefits of these diagnostic and therapeutic advances have been largely confined to high-income countries (HICs), where many once fatal conditions can now be treated, with mortality rates under 10 %. In contrast, mortality rates from hospital-based data in low- and middle-income countries (LMICs) for common anomalies often rise to 20--85 % \[[@CR2]--[@CR17]\]. Patients with immediately life-threatening conditions may die in transit or at home, and never be entered into such hospital-based measures \[[@CR18], [@CR19]\]; the resultant hidden mortality represents an oft-underestimated addition to the burden of disease. This review article will summarize the growing body of knowledge on surgical congenital anomalies in LMICs and will highlight key research recommendations. An expanded version of this review will be published as a book chapter in *Disease Control Priorities 3, Volume 3: Essential Surgery*.

Congenital anomalies and the global burden of disease {#Sec2}
=====================================================

Congenital anomalies account for a staggering 25.3--38.8 million disability-adjusted life-years (DALYs) worldwide \[[@CR20], [@CR21]\]. DALYs are a well established metric for measuring the burden of disease in terms of both mortality and morbidity; 1 DALY is 1 healthy year of life lost due to disability or premature death. The World Health Organization's (WHO) recent global burden of disease (GBD) study reports that anomalies rank 17th in causes of disease burden \[[@CR20]\]. While impressive, these figures are likely underestimates due to the limited number of anomalies included and the difficulties in evaluating incidence, morbidity, and mortality. Only six anomalies were assigned disability weights in the previous 2004 estimates, and new disability weights were not estimated for congenital anomalies in 2012 \[[@CR21], [@CR22]\]. Some researchers have tried to fill the gap with evidence-based estimates of selected disability-weights \[[@CR23]\]. Of the conditions measured in the GBD study, cardiac defects represent the greatest overall burden, and, with neural tube defects and cleft lip and palate, cause 21 million DALYs. Of these, 57 %, or 12 million are estimated to be surgically avertable if outcomes in HICs could be achieved in LMICs \[[@CR24]\]. The GBD study also reports 361 DALYs per 1,000 population globally \[[@CR20]\]. Strikingly, congenital anomalies may be responsible for up to 120 DALYs per 1,000 children \[[@CR25]\].

In general, current estimates of the surgical burden of disease are considered a "best educated guess," given the "near total lack of pertinent data" \[[@CR26]\]. Even less is known about pediatric surgical disease \[[@CR27]\]. Extant research paints a brutal picture of the potential scope and human cost of pediatric surgical disease.

Incidence, prevalence and treatment of congenital anomalies in LMICs {#Sec3}
====================================================================

A total of 94 % of anomalies occur in LMICs \[[@CR28]\]. Higher fertility rates translate to higher birth rates and net prevalence of anomalies. In addition, the frequency of pregnancy termination following prenatal diagnosis of a congenital anomaly is lower in many LMICs than in HICs. In part, this difference stems from the fact that elective pregnancy termination following prenatal diagnosis may be less available in certain LMICs than in HICs. Despite a global trend towards liberalization of termination laws, legal and procedural pushback limit access to pregnancy termination services in many countries around the world \[[@CR29]\].

Incidence (the frequency with which a disease occurs in a given population) is also higher in LMICs. This jump has been attributed to an interaction of multiple contextual factors, including increased nutritional deficiency, prevalence of intrauterine infection, exposure to teratogens, and self-medication with unsupervised drugs or traditional remedies \[[@CR30], [@CR31]\]. Although decreasing the birth rate may reduce the net prevalence of congenital anomalies, most anomalies cannot otherwise be prevented and must be treated surgically.

Many LMICs lack rigorous congenital anomaly surveillance programs, making accurate calculations of incidence and prevalence difficult \[[@CR31]\]. Current calculations, which range from 4 to 12 cases per 1,000 births, are likely underestimates due to stigma and exclusion \[[@CR32]--[@CR34]\]. In addition, the emergent nature of some anomalies can skew incidence and prevalence data. Children with non-immediately life-threatening anomalies are more likely to survive until treatment than children with immediately life-threatening conditions. Hospital-based data therefore inherently biases the perception of relative incidence and prevalence such that immediately life-threatening conditions may appear to have a lower incidence than non-immediately life-threatening anomalies \[[@CR35]\]. Population-based surveys---which directly collect data from non-centralized sites---represent one approach to addressing this challenge \[[@CR25]\].

The burden of disease associated with congenital anomalies in LMICs is most often calculated as the mortality rate over a given period of time. These data can be challenging to analyze in LMICs. In Benin, for example, only 0.8 % of nearly 1,100 neonatal deaths were investigated with an autopsy. In all examined cases, autopsy provided additional information on the cause of death \[[@CR36]\]. Additionally, non-fatal anomalies can result in extensive, ongoing morbidity. The burden of disease is grossly underestimated if measures of this impairment are not included. Indeed, anomalies resulting in visible deformity (such as clubfoot and cleft lip) or non-visible anomalies that cause chronic disability may also cause stigmatization, which can trigger abandonment or infanticide. An 'incurable' anomaly may endanger the whole family's well-being, as key resources must be allocated to care for the afflicted child. Families may fracture, with one or both parents leaving the child with other family members. While extant calculations of the burden of disease neglect to measure these harms, these calculations do highlight marked disparities in survival rates between HICs and LMICs.

Heightened mortality rates stem from a complex web of social, economic, and geographic factors. In LMICs, many births occur at home, either with no attendants or with traditional birth attendants; pejorative cultural beliefs or ignorance about possible cures for defects may prevent families from seeking treatment. If families do seek care, they must often travel great distances to reach medical facilities. Hypothermia is common following unsupervised transport over long distances, with severe repercussions on outcomes \[[@CR13], [@CR14], [@CR37]\]. Misdiagnosis as better known infectious diseases is common, as are added delays in diagnosis for non-visible anomalies. These challenges are exacerbated by the paucity of specialized providers in LMICs. One pediatric general surgeon may serve millions of children \[[@CR38]\], and physicians performing pediatric surgery may have little or no pediatric surgery training \[[@CR39], [@CR40]\]. While North America has an estimated one pediatric cardiac surgeon per 3 million people, sub-Saharan Africa has one per 38 million people \[[@CR41]\]; 75 % of the world's population is estimated to have no access to cardiac surgery \[[@CR42]\]. Similarly, one-third of the world's population is covered by one-twentieth of its neurosurgeons \[[@CR43]\]. Delays in referring patients from local health centers to medical centers with specialized surgical capacity, and the financial burden of treatment on families, also limit the accessibility of treatment for congenital anomalies.

The power of pediatric surgery to reduce the global burden of disease {#Sec4}
=====================================================================

Only a small body of literature evaluates the potential of surgery to reduce the burden of disease associated with congenital anomalies in terms of DALYs averted or cost effectiveness. Yet these foundational studies have provided compelling evidence that pediatric surgery represents a cost-effective intervention with the potential to avert over two-thirds of the DALYs associated with birth defects \[[@CR24], [@CR25], [@CR34], [@CR44]--[@CR46]\]. Favorable outcomes have been reported in HICs for anomalies such as anorectal malformations and congenital diaphragmatic hernia \[[@CR47]\]. In LMICs, the human capital approach to cleft lip and palate repair has provided very favorable cost-effectiveness analysis (CEA) estimates. An extension of this methodology to treatment for hydrocephalus in Uganda yielded a cost of \$US59--126 per DALY averted \[[@CR48]\]. Surgical repair of congenital inguinal hernias in Uganda was estimated to have an incremental cost-effectiveness ratio (ICER) of \$US12/DALY averted \[[@CR49]\]. Another recent report from Cambodia estimated a CEA of \$US99/DALY averted over 3 months for reconstructive surgery for an array of anomalies \[[@CR50]\].

Critically, treating congenital anomalies may translate into a significantly greater reduction in the economic burden of disease than that cited above. Since children represent the future economic engine powering LMICs, the value of investing in pediatric surgery also encompasses the future socioeconomic well-being of LMICs. In order to take advantage of the inherent upside to treating congenital disease at its inception, research must address the knowledge gaps that currently impede the development of effective care systems.

Recommended research priorities for pediatric surgery in LMICs {#Sec5}
==============================================================

Based on the available literature, research priorities to improve pediatric surgery capacity and reduce the burden of disease attributable to congenital anomalies include the following:Epidemiology, prevalence, and incidence of disease. Epidemiology may vary locally, but additional data are needed \[[@CR51]\]. Registries for selected anomalies may assist in improving surveillance (e.g. by participation in the International Clearinghouse for Birth Defects Surveillance and Research). Evaluation of hidden mortality and morbidity will better approximate the true burden of disease.Pediatric surgical capacity at all levels of the health system. Guidelines for minimum human resources and infrastructure for countries at different levels of development. While the WHO Situational Analysis Tool (which evaluates gaps in the availability of emergency and essential surgical care) only includes two items pertaining to pediatric surgical care, an alternative capacity tool has recently been proposed \[[@CR52]\]. This tool could be refined and further evaluated as it is piloted in different countries. While surgical outreach programs tackle the backlog of non-emergent conditions, emergent conditions require development of the whole health system. More work is needed to define and develop the mechanisms to strengthen systems for pediatric surgery.Optimized quantitative metrics of disease burden. While well accepted, DALYs are difficult to apply practically. Surgical backlogs can be calculated for congenital anomalies and can be a useful advocacy tool to estimate the resources needed to treat common, non-fatal anomalies. In MICs and HICs, many prevalent congenital anomalies are treated in the first year of life; in LICs, they are never treated or are treated years later, after children have suffered unnecessary complications. Improved measurements of the burden imposed by delayed access to care have not yet been developed. However, as DALYs are currently the standard metric, calculating new or better disability-weights for a broad range of congenital anomalies is also a viable means by which to improve meaningful evaluation of the contribution of congenital anomalies to the global burden of disease.Models for the integration of pediatric surgical services within existing child health initiatives. Large-scale child health initiatives (such as the WHO Integrated Management of Childhood Illness and Neonatal Resuscitation) have not historically included surgical care. Similarly, congenital anomalies have not been addressed through the agenda of the non-communicable disease movement, despite the fact that they are at times considered non-communicable disease (as in the WHO's recent GBD study). Many providers of children's surgical services share the concern that the surgical needs of children, if not explicitly addressed, are often neglected. Additionally, greater planning is needed between networks of specialty organizations and providers treating a broad range of congenital anomalies to collaborate where possible.Cost-effectiveness data. To the author's knowledge, only two attempts to estimate cost effectiveness for pediatric surgical wards has been made \[[@CR34], [@CR50]\]. Low-cost technical and technological innovations (such as telemedicine) hold great promise to improve perioperative care and training \[[@CR53]\]. CEA of training programs could also aid in advocacy for greater resources for training.Aligning marketing and advocacy. Greater emphasis has been directed toward selected visible, treatable anomalies (e.g. cleft lip and palate) than to a range of anomalies for which it has been more difficult to engage donor programs. Innovative strategies to improve the multidimensional measurement of the burden of disease are needed to make these treatable anomalies more salient for the public health community.

Conclusion {#Sec6}
==========

Great disparities exist in the accessibility and quality of pediatric surgical services between HICs and LMICs. This gap can only be bridged by jointly building pediatric surgical capacity in LMICs and by conducting rigorous research to better guide health system development and allocation of inherently limited resources. Local expertise and buy-in should be integrated whenever possible in order to create sustainable systems that increase long-term capacity and take advantage of the substantial potential intellectual, creative, and personnel resources of LMICs. It is an economic and moral imperative that global partners invest in pediatric surgery as a vital component of reducing the burden of disease and improving the public health and economic fortunes of LMICs. Healthy children remain the only future for society.

The authors would like to thank the editorial and research staff of the Disease Control Priorities 3 project for their support in the development of the upcoming chapter that serves as the basis for this review article.
